格隆汇2月27日丨普门科技(688389.SH)公布2025年度业绩快报，2025年度，公司实现营业总收入10.38亿 元，同比减少9.60%；实现归属于母公司所有者的净利润1.86亿元，同比减少46.12%；实现归属于母公 司所有者的扣除非经常性损益的净利润1.66亿元，同比减少49.28%。 2025年，受国内医保支付改革等行业政策影响，部分产品价格有所下调，公司国内业务收入与去年同期 相比有所下降；国际营销业务稳定增长，区域覆盖、本地化服务及市场准入工作持续推进。公司始终坚 持"聚焦主业"的发展战略，深耕体外诊断、临床医疗、皮肤医美、消费者健康市场，继续保持研发、营 销投入，不断丰富产品序列、深入拓展市场，努力提升公司的综合竞争力。 ...

Core Viewpoint - The company, Pumen Technology (688389.SH), clarified that its main business does not include the brain engineering sector, focusing instead on in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Summary by Relevant Categories Business Scope - The company's primary operations encompass in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health [2] Investor Interaction - An investor inquired whether the company's medical device business falls under the brain engineering sector, to which the company responded that it currently does not engage in this area [2]